Tabes Dorsalis diagnostic study of choice: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 9: | Line 9: | ||
=== Study of choice: === | === Study of choice: === | ||
* [[FTA-ABS|Fluorescent treponemal antibody absorbed (FTA-ABS) | * The first step laboratory test when there is a clinical suspicious toward tabes dorsalis is a [[Venereal Disease Research Laboratory test|venereal disease research laboratory test (VDRL)]] or [[Rapid plasma reagent|rapid plasma reagin (RPR)]]. | ||
* The [[FTA-ABS|fluorescent treponemal antibody absorbed (FTA-ABS) test]] should be performed when: | * [[FTA-ABS|Fluorescent treponemal antibody absorbed (FTA-ABS) test]] is the gold standard test for the diagnosis of tabes dorsalis.<ref name="pmid20846810">{{cite journal| author=Lin LR, Fu ZG, Dan B, Jing GJ, Tong ML, Chen DT et al.| title=Development of a colloidal gold-immunochromatography assay to detect immunoglobulin G antibodies to Treponema pallidum with TPN17 and TPN47. | journal=Diagn Microbiol Infect Dis | year= 2010 | volume= 68 | issue= 3 | pages= 193-200 | pmid=20846810 | doi=10.1016/j.diagmicrobio.2010.06.019 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20846810 }} </ref> | ||
** A positive [[Venereal Disease Research Laboratory test| | * The [[FTA-ABS|fluorescent treponemal antibody absorbed (FTA-ABS) test]] should be performed when: | ||
** A positive [[Venereal Disease Research Laboratory test|venereal disease research laboratory test (VDRL)]] or [[Rapid plasma reagent|rapid plasma reagin (RPR)]] is detected in the patient. | |||
==== The comparison table for diagnostic studies of choice for | ==== The comparison table for diagnostic studies of choice for tabes dorsalis ==== | ||
{| | {| | ||
|- style="background: #4479BA; color: #FFFFFF; text-align: center;" | |- style="background: #4479BA; color: #FFFFFF; text-align: center;" | ||
| Line 21: | Line 22: | ||
|- | |- | ||
! style="background: #696969; color: #FFFFFF; text-align: center;" |FTA-ABS | ! style="background: #696969; color: #FFFFFF; text-align: center;" |FTA-ABS | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |84% for detecting primary syphilis infection | | style="background: #DCDCDC; padding: 5px; text-align: center;" | | ||
* 84% for detecting primary [[syphilis]] infection | |||
* 100% sensitivity for detecting [[syphilis]] infection in secondary and tertiary stages<ref name="pmid15335137" /> | |||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |96%<ref name="pmid15335137">{{cite journal| author=Calonge N, U.S. Preventive Services Task Force| title=Screening for syphilis infection: recommendation statement. | journal=Ann Fam Med | year= 2004 | volume= 2 | issue= 4 | pages= 362-5 | pmid=15335137 | doi= | pmc=1466700 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15335137 }} </ref> | | style="background: #DCDCDC; padding: 5px; text-align: center;" |96%<ref name="pmid15335137">{{cite journal| author=Calonge N, U.S. Preventive Services Task Force| title=Screening for syphilis infection: recommendation statement. | journal=Ann Fam Med | year= 2004 | volume= 2 | issue= 4 | pages= 362-5 | pmid=15335137 | doi= | pmc=1466700 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15335137 }} </ref> | ||
|- | |- | ||
! style="background: #696969; color: #FFFFFF; text-align: center;" |VDRL/RPR | ! style="background: #696969; color: #FFFFFF; text-align: center;" |VDRL/RPR | ||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |78% to 86% for detecting primary syphilis infection | | style="background: #DCDCDC; padding: 5px; text-align: center;" | | ||
* 78% to 86% for detecting primary syphilis infection | |||
* 100% for detecting secondary syphilis infection, and 95% to 98% for detecting latent syphilis infection<ref name="pmid15335137" /> | |||
| style="background: #DCDCDC; padding: 5px; text-align: center;" |85% to 99%<ref name="pmid15335137" /> | | style="background: #DCDCDC; padding: 5px; text-align: center;" |85% to 99%<ref name="pmid15335137" /> | ||
|} | |} | ||
==References== | ==References== | ||
Revision as of 19:31, 1 March 2018
|
Tabes Dorsalis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Tabes Dorsalis diagnostic study of choice On the Web |
|
American Roentgen Ray Society Images of Tabes Dorsalis diagnostic study of choice |
|
Risk calculators and risk factors for Tabes Dorsalis diagnostic study of choice |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
Diagnostic Study of Choice
Template statements
Study of choice:
- The first step laboratory test when there is a clinical suspicious toward tabes dorsalis is a venereal disease research laboratory test (VDRL) or rapid plasma reagin (RPR).
- Fluorescent treponemal antibody absorbed (FTA-ABS) test is the gold standard test for the diagnosis of tabes dorsalis.[1]
- The fluorescent treponemal antibody absorbed (FTA-ABS) test should be performed when:
- A positive venereal disease research laboratory test (VDRL) or rapid plasma reagin (RPR) is detected in the patient.
The comparison table for diagnostic studies of choice for tabes dorsalis
| Sensitivity | Specificity | |
|---|---|---|
| FTA-ABS | 96%[2] | |
| VDRL/RPR |
|
85% to 99%[2] |
References
- ↑ Lin LR, Fu ZG, Dan B, Jing GJ, Tong ML, Chen DT; et al. (2010). "Development of a colloidal gold-immunochromatography assay to detect immunoglobulin G antibodies to Treponema pallidum with TPN17 and TPN47". Diagn Microbiol Infect Dis. 68 (3): 193–200. doi:10.1016/j.diagmicrobio.2010.06.019. PMID 20846810.
- ↑ 2.0 2.1 2.2 2.3 Calonge N, U.S. Preventive Services Task Force (2004). "Screening for syphilis infection: recommendation statement". Ann Fam Med. 2 (4): 362–5. PMC 1466700. PMID 15335137.